Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic oncology products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in onc

ology and rare diseases. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

29/05/2026

When Craig Stankiewicz was diagnosed with glioblastoma, one of the most difficult moments was telling his daughters he had cancer.

But his youngest daughter’s response surprised him: “Everybody has a superhero inside of them. It’s time for yours to go to work.”

Since then, Craig has navigated surgery, radiation, chemotherapy and two years of TTFields therapy, while raising two daughters with his wife Emily by his side at every step.

Nearly five years on, Craig is sharing his story to help others facing one of the most difficult diagnoses in oncology.

During Brain Tumor Awareness Month, Telix is sharing stories from patients, caregivers and advocates working to improve the lives of those affected by brain cancer.

Visit headforthecure.org for educational resources, information on fund-raising initiatives and patient communities.

U.S. healthcare professionals can explore diagnostic challenges in glioma at: gliomagrayareas.com

For more on Telix’s brain cancer portfolio, visit: telixpharma.com/brain

28/05/2026

Data from Part 1 of the ProstACT Global Phase 3 study will be presented as a late-breaking oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting, taking place this week in Chicago.

In this video, Pedro Barata, MD, MSc, discusses the trial, which is evaluating TLX591-Tx, Telix’s PSMA-targeted lutetium radio antibody-drug conjugate therapy candidate, in combination with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer.

Part 1 of the study was a safety and dosimetry lead-in, assessing the tolerability, biodistribution and radiation dose profile of TLX591-Tx when administered in combination with standard of care.

Learn more about our presence at ASCO here: https://telixpharma.com/telix-at-asco-2026/



TLX591-Tx has not received a marketing authorization in any jurisdiction.

Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago.ASCO 2026 will feature a late-breaking ora...
28/05/2026

Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago.

ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of ProstACT Global, Telix’s Phase 3 study of TLX591-Tx (177Lu-rosopatamab tetraxetan) in combination with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer.

The presentation will be delivered by Pedro Barata, MD, MSc, on Monday, June 1.

Telix’s renal cancer therapeutics program will also be featured at ASCO, with a poster presentation on LUTEON, a Phase 2/3 study evaluating TLX250-Tx (177Lu-girentuximab) in advanced relapsed or recurrent clear cell renal cell carcinoma.

Swipe to view the presentation details and follow the link to learn more: https://telixpharma.com/telix-at-asco-2026/

Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting.This year’s program features seven abstracts from ac...
27/05/2026

Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting.

This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel imaging approaches in clear cell renal cell carcinoma, thyroid cancer and bone marrow dosimetry.

Poster presentations will also cover prostate cancer imaging (BiPASS™), kidney cancer therapy (LUTEON), recurrent glioblastoma therapy (IPAX BrIGHT), and discovery-stage radiopharmaceutical science.
Meet us at Booth #745 to connect with and learn more about our theranostic pipeline, commercial portfolio and manufacturing capabilities.

Swipe to view the presentation details and follow the link to learn more: https://telixpharma.com/telix-at-snmmi-2026/

Join Telix’s Managing Director and Group CEO, Dr. Christian Behrenbruch, at two upcoming investor conferences in the Uni...
27/05/2026

Join Telix’s Managing Director and Group CEO, Dr. Christian Behrenbruch, at two upcoming investor conferences in the United States.

Dr. Behrenbruch will participate in the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference to discuss Telix’s growing commercial business, late-stage theranostic pipeline and global leadership in radiopharmaceuticals.

Learn more: https://telixpharma.com/news-views/telix-to-participate-in-william-blair-growth-stock-and-jefferies-global-healthcare-conferences/

Telix supports the Australian Government’s decision to expand Medicare-funded access to PSMA-PET/CT imaging for Australi...
22/05/2026

Telix supports the Australian Government’s decision to expand Medicare-funded access to PSMA-PET/CT imaging for Australian men.

From November 1, 2026, men with recurrent prostate cancer will be able to access yearly Medicare-funded PSMA-PET/CT scans for restaging, replacing the previous two-scan lifetime limit.

This is a vital step toward more equitable access to advanced molecular imaging and reflects the reality that men may need repeat imaging as their disease changes or progresses over time.

We acknowledge the advocacy of Prostate Cancer Foundation of Australia, clinicians and the men and families who helped bring attention to this important issue.

Read more on PCFA’s website here: https://www.pcfa.org.au/news-media/news/federal-government-expands-medicare-access-to-psma-pet-scans-for-prostate-cancer/

22/05/2026

That’s a wrap from ANZSNM ASM 2026 in Canberra.

Telix was proud to again support this year’s meeting, which brought together the nuclear medicine community from across Australia and New Zealand to share world-leading research and explore the continued evolution of theranostics.

Across the meeting, Telix’s therapeutic and diagnostic programs were featured in six oral presentations spanning prostate, kidney and brain cancer.

Thank you to the clinicians, researchers, nurses, allied health professionals and industry colleagues who connected with our team throughout the week, including at the ANZSNM Nurses’ Workshop, which we were pleased to support again this year.

Watch the recap below.

19/05/2026

Courtney Watson knows the pain of uncertainty that can come with brain tumor imaging — waiting for scan results, monitoring for progression, and searching for clarity in a disease where every day matters.

After losing her mother to glioblastoma less than nine months after diagnosis, Courtney dedicated herself to supporting other patients and families facing the battle with brain cancer.

Today, as Director of Programs and Communications at Head for the Cure, she helps connect the brain tumor community with support programs, advocacy initiatives and research funding opportunities.

During Brain Tumor Awareness Month, Telix is sharing stories from patients, caregivers and advocates working to improve the lives of those affected by brain cancer.

To learn more about Head for the Cure, including upcoming 5K runs and walks and patient support resources, visit: headforthecure.org

U.S. healthcare professionals can explore diagnostic challenges in glioma at: gliomagrayareas.com

For more on Telix’s brain cancer portfolio, visit: telixpharma.com/brain

Telix has completed enrolment in the IPAX-2 Phase 1 study evaluating the safety and tolerability of TLX101-Tx (¹³¹I-iodo...
18/05/2026

Telix has completed enrolment in the IPAX-2 Phase 1 study evaluating the safety and tolerability of TLX101-Tx (¹³¹I-iodofalan) in combination with post-surgical standard-of-care treatment in patients with newly diagnosed glioblastoma.

The maximum administered dose was reached with no dose-limiting toxicities observed to date.

This milestone marks an important step forward in the continued development of Telix’s LAT1-targeted therapeutic candidate for one of the most aggressive and difficult-to-treat cancers.

TLX101-Tx is also being evaluated in the pivotal IPAX BrIGHT trial, which is actively enrolling and dosing patients with recurrent glioblastoma in combination with lomustine chemotherapy.

Read more: https://telixpharma.com/news-views/ipax-2-study-of-tlx101-tx-in-first-line-glioblastoma-completes-enrolment-and-confirms-dosing/

NCT05450744

TLX101-Tx has not received a marketing authorization in any jurisdiction.

Telix has announced collaboration initiatives with EDAP TMS and Profound Medical, leading developers of minimally invasi...
15/05/2026

Telix has announced collaboration initiatives with EDAP TMS and Profound Medical, leading developers of minimally invasive and image-guided ablative technologies for prostate cancer.

The collaborations will explore the investigational use of Telix’s PSMA-PET imaging agents, Gozellix® (kit for the preparation of 68Ga-PSMA-11 injection) and Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection), across emerging treatment workflows for localized prostate cancer, including robotic high-intensity focused ultrasound (HIFU) and transurethral ultrasound ablation (TULSA).

Activities will focus on patient selection, treatment planning and post-treatment monitoring, with evidence generated expected to help inform best practice and support the integration of molecular imaging into evolving prostate cancer treatment paradigms.

Read more: https://telixpharma.com/news-views/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches/

PSMA-PET imaging is not currently approved for specific treatment-planning indications associated with these emerging therapies.

Telix is in Canberra this week for the ANZSNM Annual Scientific Meeting 2026. We're proud to support the premier event f...
14/05/2026

Telix is in Canberra this week for the ANZSNM Annual Scientific Meeting 2026.

We're proud to support the premier event for nuclear medicine in Australia and New Zealand, with Telix's diagnostic and therapeutic programs featured across six oral presentations spanning prostate, kidney, and brain cancer.

Come meet the team at booth #29 to learn more about Telix's extensive late-stage theranostic pipeline, along with our associated medical technologies, AI tools, and opportunities for collaboration.

Telix is also pleased to again support the ANZSNM Nurses' Workshop, bringing together nuclear medicine nurses and allied health professionals from across Australia and New Zealand to share clinical experience and advance best practice in theranostic care.

Swipe to view all presentations, and follow the link to learn more about Telix at ANZSNM ASM: https://telixpharma.com/telix-at-anzsnm-2026/

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share